Recent perspectives of endocrine therapy for breast cancer.

被引:29
作者
Utsumi T. [1 ]
Kobayashi N. [1 ]
Hanada H. [1 ]
机构
[1] Department of Breast Surgery, Fujita Health University School of Medicine
关键词
Endocrine therapy; Aromatase inhibitor; Breast cancer;
D O I
10.2325/jbcs.959
中图分类号
学科分类号
摘要
The choice of endocrine therapy for breast cancer depends on the menopausal status and stage of disease. Endocrine therapy remains the first choice and most important component in the treatment of hormone sensitive non-life threatening advanced breast cancer. In premenopausal women with metastatic disease, the combination of a luteinizing hormone-releasing hormone (LH-RH) agonist plus tamoxifen is reasonable as first-line endocrine therapy. In postmenopausal patients with recurrent disease progressing after or during adjuvant tamoxifen, third-generation aromatase inhibitors (AIs) are the preferred first-line endocrine treatment. Many premenopausal and postmenopausal women with hormone responsive breast cancer benefit from sequential use of endocrine therapies at the time of disease progression. Recent clinical trials designs have been implemented, employing AIs as monotherapy in postmenopausal breast cancer patients, as first-line adjuvant therapy, and in sequence either 2-3 or 5 years, with initial tamoxifen. Emerging results from these trials indicate an advantage to patients for any of these strategies, and most international guidelines now suggest the use of an AI in the adjuvant setting in postmenopausal women. The use of endocrine treatment for metastatic and early breast cancer will be reviewed here.
引用
收藏
页码:194 / 199
页数:5
相关论文
共 339 条
[31]  
Sylvester R(2005)Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455-462
[32]  
Forward DP(2003)(A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer) N Engl J Med 349 1793-1802
[33]  
Cheung KL(undefined)undefined undefined undefined undefined-undefined
[34]  
Jackson L(undefined)undefined undefined undefined undefined-undefined
[35]  
Robertson JF(undefined)undefined undefined undefined undefined-undefined
[36]  
Buzdar A(undefined)undefined undefined undefined undefined-undefined
[37]  
Jonat W(undefined)undefined undefined undefined undefined-undefined
[38]  
Howell A(undefined)undefined undefined undefined undefined-undefined
[39]  
Jones SE(undefined)undefined undefined undefined undefined-undefined
[40]  
Blomqvist C(undefined)undefined undefined undefined undefined-undefined